<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01264445</url>
  </required_header>
  <id_info>
    <org_study_id>IAVI B002</org_study_id>
    <nct_id>NCT01264445</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines</brief_title>
  <official_title>A Phase I Double-blinded, Placebo-controlled, Randomized Trial in HIV-uninfected, Healthy Adult Volunteers to Evaluate the Safety and Immunogenicity of an Adjuvanted GSK HIV Vaccine Administered With Ad35-GRIN Investigational Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International AIDS Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>International AIDS Vaccine Initiative</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of an&#xD;
      adjuvanted GSK investigational HIV vaccine and Ad35-GRIN in 4 different regimens at months 1,&#xD;
      2, 3, and 4.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Volunteers will be screened up to 42 days before vaccination (up to 90 days for Ad35&#xD;
      neutralizing antibody) and will be followed for 12 months after the last vaccination (16&#xD;
      months total participation).&#xD;
&#xD;
      It is estimated that it will take approximately 5 months to complete enrolment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of an adjuvanted HIV protein vaccine in prime-boost combinations with AD35-GRIN or coadministered with AD35-GRIN</measure>
    <time_frame>16 months</time_frame>
    <description>Safety of an adjuvanted (dose escalation for adjvans) HIV protein vaccine given as prime or boost in combination with Ad35-GRIN or co-administered with Ad35-GRIN</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of an adjuvanted HIV protein vaccine given in different prime-boost regimens with Ad35-GRIN or coadminisitered with Ad35-GRIN</measure>
    <time_frame>16 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvanted GSK investigational HIV vaccine at Months 0 and 1 followed by Ad35-GRIN investigational HIV vaccine at Month 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvanted GSK investigational HIV vaccine at Months 0 and 1 followed by Ad35-GRIN investigational HIV vaccine at Month 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad35-GRIN investigational HIV vaccine at Month 0 followed by Adjuvanted GSK investigational HIV vaccine at Months 3 and 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvanted GSK investigational HIV vaccine and Ad35-GRIN investigational HIV vaccine co-administered (simultaneous administration with separate injections)at Months 0, 1, and 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted GSK investigational HIV vaccine formulation 1</intervention_name>
    <description>Receive at Months 0 and 1</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted GSK investigational HIV vaccine formulation 2</intervention_name>
    <description>Receive at Months 0 and 1</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad35 investigational HIV vaccine</intervention_name>
    <description>Receive at Month 0</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted GSK investigational HIV vaccine formulation 2</intervention_name>
    <description>Receive at Months 3 and 4</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted GSK investigational HIV vaccine formulation 2</intervention_name>
    <description>Receive at Months 0, 1, and 4</description>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad35 investigational HIV vaccine</intervention_name>
    <description>Receive at Month 4</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad35 investigational HIV vaccine</intervention_name>
    <description>Receive at Months 0, 1, and 4</description>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo (saline)</intervention_name>
    <description>(Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males and females, as assessed by a medical history, physical exam, and&#xD;
             laboratory tests&#xD;
&#xD;
          2. At least 18 years of age on the day of screening and has not reached his/her 41st&#xD;
             birthday on the day of first vaccination&#xD;
&#xD;
          3. Willing to comply with the requirements of the protocol and available for follow-up&#xD;
             for the planned duration of the study (screening plus 16 months)&#xD;
&#xD;
          4. In the opinion of the Principal Investigator or designee and based on Assessment of&#xD;
             Informed Consent Understanding results, has understood the information provided and&#xD;
             potential risks linked to vaccination and participation in the trial. Written informed&#xD;
             consent needs to be provided by the volunteer before any study-related procedures are&#xD;
             performed&#xD;
&#xD;
          5. Willing to undergo HIV testing, risk reduction counselling, receive HIV test results&#xD;
             and committed to maintaining low risk behaviour for the trial duration&#xD;
&#xD;
          6. If a female of childbearing potential (not menopausal or anatomically sterile),&#xD;
             willing to use an effective non-barrier method of contraception (hormonal&#xD;
             contraceptive; intra-uterine device), from screening until four months after last&#xD;
             vaccination. All female volunteers must be willing to undergo urine pregnancy tests at&#xD;
             time points as indicated in the study protocol and must test negative prior to each&#xD;
             vaccination.&#xD;
&#xD;
          7. If sexually active male (who is not anatomically sterile), willing to use an effective&#xD;
             method of contraception (such as consistent condom use) from the day of first&#xD;
             vaccination until 4 months after the last vaccination&#xD;
&#xD;
          8. Willing to forgo donations of blood or any other tissues during the study and, for&#xD;
             those who test HIV positive after vaccination, until the anti-HIV antibody titres&#xD;
             become undetectable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Confirmed HIV-1 or HIV-2 infection&#xD;
&#xD;
          2. Any clinically relevant abnormality on history or examination including history of&#xD;
             immunodeficiency, malignancy or autoimmune disease; use of systemic corticosteroids&#xD;
             (&lt;2 weeks use of topical or inhaled steroids is permitted); immunosuppressive,&#xD;
             anticancer, anti-tuberculosis or other medications considered significant by the&#xD;
             investigator within the previous 6 months&#xD;
&#xD;
          3. Any clinically significant acute or chronic medical condition that is considered&#xD;
             progressive, or in the opinion of the investigator, makes the volunteer unsuitable for&#xD;
             participation in the study&#xD;
&#xD;
          4. Detection of Ad35-specific serum neutralizing antibody&#xD;
&#xD;
          5. Reported high-risk behaviour for HIV infection within 6 months prior to first&#xD;
             vaccination, as defined by the protocol.&#xD;
&#xD;
          6. If female, pregnant or planning a pregnancy within 4 months after last vaccination; or&#xD;
             lactating&#xD;
&#xD;
          7. Unstable asthma (e.g. sudden acute attacks occurring without an obvious trigger) or&#xD;
             asthma requiring:&#xD;
&#xD;
               -  Daily steroid or long acting beta-agonist prevention&#xD;
&#xD;
               -  Hospitalization in the last two years&#xD;
&#xD;
          8. Bleeding disorder that was diagnosed by a physician e.g., factor deficiency,&#xD;
             coagulopathy or platelet disorder that requires special precautions. (A volunteer who&#xD;
             states that he or she has easy bruising or bleeding, but does not have a formal&#xD;
             diagnosis and has intramuscular (IM) injections and blood draws without any adverse&#xD;
             experience is eligible)&#xD;
&#xD;
          9. History of splenectomy&#xD;
&#xD;
         10. Any abnormal laboratory parameters as defined by the protocol;&#xD;
&#xD;
         11. Receipt of live-attenuated vaccine within the previous 60 days (live attenuated flu&#xD;
             vaccine within 14 days) or planned receipt within 60 days after vaccination with&#xD;
             Investigational Product; or receipt of other vaccine (e.g. pneumococcal), allergy&#xD;
             treatment with antigen injections or tuberculin skin test within the previous 14 days&#xD;
             or planned receipt within 14 days after vaccination with Investigational Product&#xD;
&#xD;
         12. Receipt of blood transfusion or blood-derived products within the previous 6 months&#xD;
&#xD;
         13. Participation in another clinical trial of an Investigational Product currently,&#xD;
             within the previous 3 months or expected participation during this study&#xD;
&#xD;
         14. Prior receipt of another investigational HIV vaccine candidate (note: receipt of an&#xD;
             HIV vaccine placebo will not exclude a volunteer from participation if documentation&#xD;
             is available and the IAVI Medical Monitor gives approval)&#xD;
&#xD;
         15. History of severe local or systemic reactogenicity to vaccines (e.g. anaphylaxis,&#xD;
             respiratory difficulty, angioedema)&#xD;
&#xD;
         16. History of severe allergic reactions to any substance requiring hospitalization or&#xD;
             emergency medical care (e.g. Steven-Johnson syndrome, bronchospasm or hypotension)&#xD;
&#xD;
         17. Known sensitivity to sulphite, aspirin or aminoglycoside antibiotics (e.g. amikacin,&#xD;
             arbekacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, streptomycin,&#xD;
             tobramycin, etc)&#xD;
&#xD;
         18. Confirmed diagnosis of active hepatitis B (HBsAg), hepatitis C (HCV antibodies),&#xD;
             active syphilis or active tuberculosis&#xD;
&#xD;
         19. History of severe neurological disorder, seizure or psychiatric disorder (e.g&#xD;
             schizophrenia, severe psychosis, bipolar disorder requiring therapy, suicidal attempt&#xD;
             or ideation)&#xD;
&#xD;
         20. For those volunteers at clinical centres participating in ophthalmic examinations, any&#xD;
             clinically significant abnormality found on baseline ophthalmic examination.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gloria S Omosa-Manyonyi, MBChB,DPH,DLSHTM, MSc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kenya AIDS Vaccine Initiative</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juliet Mpendo, MBChB, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uganda Virus Research Institute-IAVI</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eugene Ruzagira, MBChB MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Research Council-UVRI Uganda Research Unit on AIDS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elwyn Chomba, BSc, MBChB, DCH, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zambia-Emory HIV Research Project</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kenya AIDS Vaccine Initiative</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uganda Virus Research Institute-IAVI</name>
      <address>
        <city>Entebbe</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Council</name>
      <address>
        <city>Masaka</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zambia-Emory HIV Research Project</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>Uganda</country>
    <country>Zambia</country>
  </location_countries>
  <link>
    <url>http://www.iavi.org</url>
    <description>International AIDS Vaccine Initiative</description>
  </link>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>December 20, 2010</study_first_submitted>
  <study_first_submitted_qc>December 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2010</study_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

